127 related articles for article (PubMed ID: 38031985)
1. First-Line Tislelizumab for Advanced or Metastatic Esophageal Squamous Cell Carcinoma:A Cost-Effectiveness Analysis.
Zheng Z; Chen H; Cai H; Zhu H
Expert Rev Pharmacoecon Outcomes Res; 2024 Mar; 24(3):397-404. PubMed ID: 38031985
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness analysis of tislelizumab vs. camrelizumab for the treatment of second-line locally advanced or metastatic esophageal squamous cell carcinoma.
Chen P; Fu C; Shen L; Fei Z; Luo M; Chen Y; Li H
BMC Health Serv Res; 2024 May; 24(1):676. PubMed ID: 38807104
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness analysis of tislelizumab plus chemotherapy as the first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma in China.
He C; Mi X; Xu G; Xu X; Xin W; Zhong L; Zhu J; Shu Q; Fang L; Ding H
PLoS One; 2024; 19(5):e0302961. PubMed ID: 38748691
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness analysis of PD-1 inhibitors as second-line therapy for advanced or metastatic esophageal squamous cell carcinoma in China: an economic evaluation based on network meta-analysis.
Liu S; Zhao L; Shi F; Kuai L; Liu R; Tang J
Int J Clin Pharm; 2024 Jun; 46(3):675-683. PubMed ID: 38407692
[TBL] [Abstract][Full Text] [Related]
5. Immune checkpoint inhibitors as the second-line treatment for advanced esophageal squamous cell carcinoma: a cost-effectiveness analysis based on network meta-analysis.
Yang X; Zheng X; Hu S; Huang J; Zhang M; Huang P; Wang J
BMC Cancer; 2024 May; 24(1):654. PubMed ID: 38811891
[TBL] [Abstract][Full Text] [Related]
6. Tislelizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy as First-Line Treatment for Chinese Patients with Advanced Esophageal Squamous Cell Carcinoma: A Cost-Effectiveness Analysis.
Lu S; Lou Y; Rong Y; Huang Z; Lin X; Chen J; Luo K
Clin Drug Investig; 2023 Aug; 43(8):643-652. PubMed ID: 37542611
[TBL] [Abstract][Full Text] [Related]
7. Cost-Effectiveness Analysis of Tislelizumab Plus Chemotherapy as First-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma in China.
Zhou C; Wei J; Xu K; Lin Y; Zhang L; Li X
Risk Manag Healthc Policy; 2023; 16():2447-2458. PubMed ID: 38024498
[TBL] [Abstract][Full Text] [Related]
8. Economic evaluation of tislelizumab versus chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma in China.
Shi F; He Z; Su H; Wang L; Han S
Front Pharmacol; 2022; 13():961347. PubMed ID: 36467065
[No Abstract] [Full Text] [Related]
9. Tislelizumab plus chemotherapy is more cost-effective than chemotherapy alone as first-line therapy for advanced non-squamous non-small cell lung cancer.
Liang X; Chen X; Li H; Li Y
Front Public Health; 2023; 11():1009920. PubMed ID: 36794070
[TBL] [Abstract][Full Text] [Related]
10. Tislelizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma in China: a cost-effectiveness analysis.
Zheng Z; Lin Y; Cai H
Front Public Health; 2024; 12():1356244. PubMed ID: 38562257
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness analysis of tislelizumab plus chemotherapy as the first-line treatment for advanced or metastatic esophageal squamous cell carcinoma in China.
Liu Y; Shao R
Front Pharmacol; 2024; 15():1225076. PubMed ID: 38813103
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness analysis of tislelizumab in combination with chemotherapy for the first-line treatment of patients with metastatic or recurrent nasopharyngeal carcinoma in China.
Tang YK; Xu Z; Ye ZM; Li SR; Zhou Q
Head Neck; 2024 Jan; 46(1):5-14. PubMed ID: 37846175
[TBL] [Abstract][Full Text] [Related]
13. Tislelizumab in advanced/metastatic esophageal squamous cell carcinoma: health-related quality of life in Asian patients.
Kim SB; Van Cutsem E; Ajani J; Shen L; Barnes G; Ding N; Tao A; Xia T; Zhan L; Kato K
Curr Med Res Opin; 2024 Jan; 40(1):69-75. PubMed ID: 37846080
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness analysis of toripalimab plus chemotherapy for patients with advanced esophageal squamous cell carcinoma in China.
Kang S; Wang X; Pan Z; Liu H
Expert Rev Pharmacoecon Outcomes Res; 2024 Feb; 24(2):285-292. PubMed ID: 37855081
[TBL] [Abstract][Full Text] [Related]
15. First-line nivolumab plus ipilimumab or chemotherapy
Cao X; Cai H; Li N; Zheng B; Zheng Z; Liu M
Ther Adv Med Oncol; 2022; 14():17588359221122733. PubMed ID: 36147862
[TBL] [Abstract][Full Text] [Related]
16. Second-line tislelizumab versus chemotherapy in Japanese patients with advanced or metastatic esophageal squamous cell carcinoma: subgroup analysis from RATIONALE-302.
Hara H; Satoh T; Kojima T; Tsushima T; Sunakawa Y; Okada M; Ding N; Wu H; Li L; Yu T; Barnes G; Kato K
Esophagus; 2024 Apr; 21(2):102-110. PubMed ID: 38240916
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness analysis of first-line tislelizumab plus chemotherapy for recurrent or metastatic nasopharyngeal cancer.
Pei Z; Xiao N; Yang P
Front Pharmacol; 2023; 14():1265784. PubMed ID: 37964872
[No Abstract] [Full Text] [Related]
18. Cost-effectiveness of sintilimab plus chemotherapy versus chemotherapy alone as first-line treatment of locally advanced or metastatic oesophageal squamous cell carcinoma.
Liu L; Wang L; Chen L; Ding Y; Zhang Q; Shu Y
Front Immunol; 2023; 14():1092385. PubMed ID: 36756110
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness and cost-effectiveness analysis of 11 treatment paths, seven first-line and three second-line treatments for Chinese patients with advanced wild-type squamous non-small cell lung cancer: A sequential model.
Zhao M; Shao T; Chi Z; Tang W
Front Public Health; 2023; 11():1051484. PubMed ID: 36908446
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness analysis of serplulimab in combination with cisplatin plus 5-fluorouracil chemotherapy compared to cisplatin plus 5-fluorouracil chemotherapy as first-line treatment for advanced or metastatic esophageal squamous cell carcinoma in China.
Lin YT; Zhou CC; Xu K; Zhang MD; Li X
Ther Adv Med Oncol; 2023; 15():17588359231213621. PubMed ID: 38028139
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
